• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5107272)   Today's Articles (2810)
For: Boon WPC, Moors EHM, Meijer A, Schellekens H. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther 2010;88:848-53. [PMID: 20962774 DOI: 10.1038/clpt.2010.207] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Number Cited by Other Article(s)
1
Marín Penella G. The Epistemic Policies of Anti-Ageing Medicines in the European Union. HEALTH CARE ANALYSIS 2024:10.1007/s10728-024-00497-9. [PMID: 39560904 DOI: 10.1007/s10728-024-00497-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/01/2024] [Indexed: 11/20/2024]
2
Pasmooij AMG, Mol PGM, Bot JC, Leufkens HGM. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clin Pharmacol Ther 2024;116:64-71. [PMID: 38679943 DOI: 10.1002/cpt.3275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Accepted: 04/05/2024] [Indexed: 05/01/2024]
3
Ghadanian M, Schafheutle E. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations. Ther Innov Regul Sci 2024;58:79-113. [PMID: 37861859 PMCID: PMC10764419 DOI: 10.1007/s43441-023-00574-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Accepted: 08/21/2023] [Indexed: 10/21/2023]
4
Bloem LT, Schelhaas J, López-Anglada L, Herberts C, van Hennik PB, Tenhunen O. European Conditional Marketing Authorization in a Rapidly Evolving Treatment Landscape: A Comprehensive Study of Anticancer Medicinal Products in 2006-2020. Clin Pharmacol Ther 2023. [PMID: 37129347 DOI: 10.1002/cpt.2906] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Accepted: 03/20/2023] [Indexed: 05/03/2023]
5
Mills M. HTA Barriers for Conditional Approval Drugs. PHARMACOECONOMICS 2023;41:529-545. [PMID: 36821044 DOI: 10.1007/s40273-023-01248-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 01/30/2023] [Indexed: 05/10/2023]
6
How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. Health Policy 2022;126:1130-1143. [DOI: 10.1016/j.healthpol.2022.08.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 07/13/2022] [Accepted: 08/02/2022] [Indexed: 11/17/2022]
7
Bloem LT, Bot RE, Mantel-Teeuwisse AK, van der Elst ME, Sonke GS, Klungel OH, Leufkens HGM, Hoekman J. Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: a comparison with standard approved cancer drugs. Br J Clin Pharmacol 2021;88:2169-2179. [PMID: 34779004 PMCID: PMC9303888 DOI: 10.1111/bcp.15141] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 10/26/2021] [Accepted: 11/07/2021] [Indexed: 12/01/2022]  Open
8
Bloem LT, Vreman RA, Peeters NWL, Hoekman J, van der Elst ME, Leufkens HGM, Klungel OH, Goettsch WG, Mantel-Teeuwisse AK. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clin Transl Sci 2021;14:1566-1577. [PMID: 33786991 PMCID: PMC8301545 DOI: 10.1111/cts.13027] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 03/02/2021] [Accepted: 03/09/2021] [Indexed: 11/30/2022]  Open
9
Physicians' attitudes towards accelerated access to medicines. HEALTH ECONOMICS POLICY AND LAW 2019;16:154-169. [PMID: 31668160 DOI: 10.1017/s1744133119000288] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
10
Muensterman ET, Luo Y, Parker JM. Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status. Ther Innov Regul Sci 2019:2168479019874062. [PMID: 31558045 DOI: 10.1177/2168479019874062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
11
Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan. Int J Mol Sci 2019;20:ijms20153801. [PMID: 31382625 PMCID: PMC6696404 DOI: 10.3390/ijms20153801] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Revised: 07/23/2019] [Accepted: 08/01/2019] [Indexed: 11/17/2022]  Open
12
Sudhop T, Brun NC, Riedel C, Rosso A, Broich K, Senderovitz T. Master protocols in clinical trials: a universal Swiss Army knife? Lancet Oncol 2019;20:e336-e342. [DOI: 10.1016/s1470-2045(19)30271-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 03/25/2019] [Accepted: 03/26/2019] [Indexed: 12/27/2022]
13
Lexchin J. Health Canada’s Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis. INTERNATIONAL JOURNAL OF HEALTH SERVICES 2018;49:294-305. [DOI: 10.1177/0020731418821007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
14
Hoekman J, Boon W. Changing standards for drug approval: A longitudinal analysis of conditional marketing authorisation in the European Union. Soc Sci Med 2018;222:76-83. [PMID: 30605802 DOI: 10.1016/j.socscimed.2018.12.025] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 12/11/2018] [Accepted: 12/18/2018] [Indexed: 02/06/2023]
15
Sanada S. Finding the Optimal Regulatory Systems to Facilitate the Development of Novel and Advanced Therapeutics. Circ Rep 2018;1:43-45. [PMID: 33693112 PMCID: PMC7925127 DOI: 10.1253/circrep.cr-18-0019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]  Open
16
Pace J, Ghinea N, Kerridge I, Lipworth W. An ethical framework for the creation, governance and evaluation of accelerated access programs. Health Policy 2018;122:984-990. [DOI: 10.1016/j.healthpol.2018.07.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Revised: 07/07/2018] [Accepted: 07/14/2018] [Indexed: 12/23/2022]
17
Pace J, Ghinea N, Kerridge I, Lipworth W. Accelerated Access to Medicines: An Ethical Analysis. Ther Innov Regul Sci 2017;51:157-163. [DOI: 10.1177/2168479016674043] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
18
Pace J, Ghinea N, Kerridge I, Lipworth W. Caution needed in introduction of provisional approvals for medicines. Intern Med J 2017;47:1321-1324. [PMID: 29105267 DOI: 10.1111/imj.13605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Revised: 05/30/2017] [Accepted: 05/31/2017] [Indexed: 11/28/2022]
19
Webster A. Regenerative medicine and responsible research and innovation: proposals for a responsible acceleration to the clinic. Regen Med 2017;12:853-864. [DOI: 10.2217/rme-2017-0028] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]  Open
20
LEGITIMACY OF MEDICINES FUNDING IN THE ERA OF ACCELERATED ACCESS. Int J Technol Assess Health Care 2017;33:700-707. [PMID: 28893332 DOI: 10.1017/s0266462317000794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
21
Faulkner A. Opening the gateways to market and adoption of regenerative medicine? The UK case in context. Regen Med 2016;11:321-30. [PMID: 27035398 DOI: 10.2217/rme-2015-0046] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]  Open
22
Nagai S, Ozawa K. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US. Int J Hematol 2016;104:73-84. [PMID: 27084259 DOI: 10.1007/s12185-016-2001-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Revised: 04/05/2016] [Accepted: 04/05/2016] [Indexed: 01/03/2023]
23
Lexchin J. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy. Br J Clin Pharmacol 2016;79:847-59. [PMID: 25393960 DOI: 10.1111/bcp.12552] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Accepted: 11/07/2014] [Indexed: 11/28/2022]  Open
24
Martinalbo J, Bowen D, Camarero J, Chapelin M, Démolis P, Foggi P, Jonsson B, Llinares J, Moreau A, O'Connor D, Oliveira J, Vamvakas S, Pignatti F. Early market access of cancer drugs in the EU. Ann Oncol 2016;27:96-105. [DOI: 10.1093/annonc/mdv506] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 10/14/2015] [Indexed: 12/24/2022]  Open
25
Banzi R, Gerardi C, Bertele' V, Garattini S. Approvals of drugs with uncertain benefit-risk profiles in Europe. Eur J Intern Med 2015;26:572-84. [PMID: 26342723 DOI: 10.1016/j.ejim.2015.08.008] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Revised: 08/07/2015] [Accepted: 08/12/2015] [Indexed: 01/02/2023]
26
Charo RA. SCIENCE AND GOVERNMENT. Yellow lights for emerging technologies. Science 2015. [PMID: 26206921 DOI: 10.1126/science.aab3885] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
27
Hoekman J, Boon WPC, Bouvy JC, Ebbers HC, de Jong JP, De Bruin ML. Use of the conditional marketing authorization pathway for oncology medicines in Europe. Clin Pharmacol Ther 2015;98:534-41. [DOI: 10.1002/cpt.174] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2015] [Accepted: 06/11/2015] [Indexed: 01/04/2023]
28
Watanabe N, Yano K, Tsuyuki K, Okano T, Yamato M. Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT 2015;2:14066. [PMID: 26052534 PMCID: PMC4449026 DOI: 10.1038/mtm.2014.66] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/17/2014] [Revised: 12/04/2014] [Accepted: 12/04/2014] [Indexed: 12/02/2022]
29
Senderowicz AM, Pfaff O. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics. Clin Cancer Res 2014;20:1445-52. [PMID: 24634467 DOI: 10.1158/1078-0432.ccr-13-1761] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
30
Boon W, Martins L, Koopmanschap M. Governance of conditional reimbursement practices in The Netherlands. Health Policy 2014;119:180-5. [PMID: 25467790 DOI: 10.1016/j.healthpol.2014.10.013] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2014] [Revised: 10/20/2014] [Accepted: 10/21/2014] [Indexed: 10/24/2022]
31
Towards a sustainable system of drug development. Drug Discov Today 2014;19:1711-1720. [DOI: 10.1016/j.drudis.2014.03.004] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 01/29/2014] [Accepted: 03/06/2014] [Indexed: 01/13/2023]
32
Adaptive approaches to licensing, health technology assessment, and introduction of drugs and devices. Int J Technol Assess Health Care 2014;30:241-9. [PMID: 24921416 DOI: 10.1017/s0266462314000191] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
33
Post-approval safety issues with innovative drugs: a European cohort study. Drug Saf 2014;36:1105-15. [PMID: 24048690 DOI: 10.1007/s40264-013-0094-y] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
34
Law MR. The characteristics and fulfillment of conditional prescription drug approvals in Canada. Health Policy 2014;116:154-61. [DOI: 10.1016/j.healthpol.2014.03.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2013] [Revised: 02/18/2014] [Accepted: 03/07/2014] [Indexed: 11/26/2022]
35
Shah RR, Roberts SA, Shah DR. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors. Br J Clin Pharmacol 2014;76:396-411. [PMID: 23362829 DOI: 10.1111/bcp.12085] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Accepted: 01/21/2013] [Indexed: 11/28/2022]  Open
36
Boudes PF. Clinical studies in lysosomal storage diseases: Past, present, and future. Rare Dis 2013;1:e26690. [PMID: 25003011 PMCID: PMC3915565 DOI: 10.4161/rdis.26690] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2013] [Revised: 09/22/2013] [Accepted: 10/03/2013] [Indexed: 01/28/2023]  Open
37
Gispen-de Wied C, Stoyanova V, Yu Y, Isaac M, Pani L, de Andres-Trelles F. The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma. Eur Neuropsychopharmacol 2012;22:804-11. [PMID: 22704716 DOI: 10.1016/j.euroneuro.2012.03.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/21/2011] [Revised: 03/13/2012] [Accepted: 03/18/2012] [Indexed: 11/16/2022]
38
Tanimoto T, Tsubokura M, Mori J, Pietrek M, Ono S, Kami M. Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin. Invest New Drugs 2012;31:473-8. [PMID: 22965890 DOI: 10.1007/s10637-012-9877-8] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2012] [Accepted: 08/30/2012] [Indexed: 11/29/2022]
39
Arnardottir AH, Haaijer-Ruskamp FM, Straus SMJ, Eichler HG, de Graeff PA, Mol PGM. Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol 2011;72:490-9. [PMID: 21501215 PMCID: PMC3175519 DOI: 10.1111/j.1365-2125.2011.03995.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2010] [Accepted: 03/28/2011] [Indexed: 11/26/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA